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Genome-wide association studies (GWASs) are the method most often used by geneticists to interrogate the
human genome, and they provide a cost-effective way to identify the genetic variants underpinning complex traits
and diseases. Most initial GWASs have focused on genetically homogeneous cohorts from European populations
given the limited availability of ethnic minority samples and so as to limit population stratification effects. Transethnic
studies have been invaluable in explaining the heritability of common quantitative traits, such as height, and in
examining the genetic architecture of complex diseases, such as type 2 diabetes. They provide an opportunity for
large-scale signal replication in independent populations and for cross-population meta-analyses to boost statistical
power. In addition, transethnic GWASs enable prioritization of candidate genes, fine-mapping of functional variants,
and potentially identification of SNPs associated with disease risk in admixed populations, by taking advantage of
natural differences in genomic linkage disequilibrium across ethnically diverse populations. Recent efforts to assess the
biological function of variants identified by GWAS have highlighted the need for large-scale replication, meta-analyses
and fine-mapping across worldwide populations of ethnically diverse genetic ancestries. Here, we review recent advances
and new approaches that are important to consider when performing, designing or interpreting transethnic GWASs, and
we highlight existing challenges, such as the limited ability to handle heterogeneity in linkage disequilibrium across
populations and limitations in dissecting complex architectures, such as those found in recently admixed populations.Introduction
Large-scale genome-wide association studies (GWASs)
have led to the discovery of thousands of genetic signals
across the human genome associated with human diseases
and quantitative traits [1]. These findings have led to sig-
nificant advances, not only in identifying functional vari-
ants and in understanding how such genetic variants can
affect disease risk, but also in our understanding of how
selective pressures and natural selection have affected the
human genome [2]. Although most GWASs originally fo-
cused on populations of European ancestry, ‘transethnic’
studies that incorporate genotype data from more than
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have an important role in genomic medicine today. Using
these transethnic analyses, several fine-mapping analyses
have highlighted the newly recognized but essential role
for regulatory and non-coding variants in disease biology
and gene regulation. Understanding how coding and non-
coding variants together can affect disease risk through
such fine-mapping and resequencing efforts is arguably
the most challenging and exciting area for genomic
medicine today, because it offers opportunities for drug
discovery or repositioning (by targeting specific mutations,
signaling receptors or biological pathways).
Despite significant advances in high-throughput geno-
typing platforms, more powerful human genome reference
panels and accurate imputation methods, major challenges
remain. One is the apparent gap between the estimated
disease heritability attributable to genetic factors (based
on family and population genetics studies) and the small
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GWASs [3]. This gap, referred to as ‘missing heritability’,
remains a significant impediment, not only to understand-
ing the role of genetic risk factors in human disease, but
also for the disease-predictive utility of such genetic infor-
mation - a much-espoused goal of genomics in the per-
sonalized medicine era. As such, the seeming incremental
gain in disease or phenotype prediction based on this
analysis of common human variation has been heavily
criticized by many in the clinical community, as it re-
mains unclear whether these results have significant
clinical utility.
Various approaches have been proposed to test the
models put forth by the genetics community to explain
the observed missing heritability [4-6]. Rare variants,
gene-environmental interactions [7], and other factors
that can contribute to phenotypic heterogeneity probably
contribute to disease heritability, as recently shown in
the context of cancer [8,9] and neuropsychiatric diseases
such as autism and attention deficit hyperactivity dis-
order [10-12]. Because the frequencies of bona fide
disease-causing genetic variants are known to vary be-
tween populations and because environmental exposures
can also be altered, there has been much interest re-
cently in the design and implementation of transethnic
studies.
Furthermore, with the sheer numbers of individuals
required to detect small to modest effect sizes, the
bolstering of all populations available across large
disease-analysis consortia is becoming more common,
particularly in the study of quantitative traits where
common international laboratory standards are used
[6,13-15]. Moreover, when designed properly, trans-
ethnic population findings enable a finer dissection of
genetic architecture within a population. Specifically, it
can be difficult to perform locus fine-mapping in intra-
ethnic studies, as pinpointing the causal variant in the
presence of strong linkage disequilibrium (LD) across a
locus tends to be difficult, as compared with studying pop-
ulations with limited LD in the same locus. This problem
has been frequently observed at several loci originally
identified from studies of European populations that have
since been fine-mapped in Asian or African populations
(Table 1).
In this review, we highlight some of the key advances
from the recent literature in which transethnic GWASs
have been used for locus discovery, replication, fine-
mapping or admixture mapping of causal variants associ-
ated with complex diseases. We also discuss advances and
challenges in the use of transethnic GWASs by highlight-
ing recently published software that apply new algorithms
to boost the power of transethnic meta-analysis by le-
veraging LD information and the underlying differences
in genetic architecture across disparate ancestral humangenomes. In addition, we provide examples of recent stud-
ies that implement these methods and highlight their
advantages and disadvantages over traditional GWAS
meta-analytic approaches. Although our review is limited
to disease-association traits, transethnic studies have also
been used in other applications, such as the analysis of
pharmacogenomics response [16-18] and of other pheno-
typic traits [19].
We conclude by noting the many challenges that
remain in using samples from multiple diverse popula-
tions. Aside from limitations in sample sizes, with limited
availability of genotyping and sequencing data from ethnic
minorities, the ability to identify a priori appropriate study
populations is difficult. For example, the currently avail-
able methods for performing transethnic meta-analysis
still face limitations in power and also have limited ability
to estimate joint effect sizes in the presence of effect
heterogeneity.
The need for transethnic genome-wide association
studies
Transethnic studies are increasingly being used to in-
crease study power by increasing the total study sample
size. This is in part because there are limited sample
sizes available for many diseases and because several
consortia across the world have been established in
countries whose populations are of diverse ancestries.
The largest transethnic studies so far include studies of
factors involved in metabolic and cardiovascular dis-
eases, including high-density lipoprotein and low-density
lipoprotein (LDL) levels [20], ischemic stroke and coron-
ary artery disease [21] and blood pressure [22]; immune
traits such as rheumatoid arthritis (RA) [23] and asthma
[24]; neurocognitive and psychiatric diseases; and com-
mon oncologic diseases, including breast cancer [25]
and prostate cancer [26].
Although a common goal in each of these large-scale
transethnic GWASs is still disease/trait locus discovery,
these studies also simultaneously make use of other fea-
tures of transethnic study designs in four ways. First,
they provide an independent replication sample set that
can overcome concerns about sub-population or cryptic
population stratification effects in single-population
GWASs [27] and that can prioritize loci for secondary
replication and sequencing studies [28]. Second, they
boost study power by increasing the sample size. Third,
they also strengthen the ability to evaluate the ‘common
disease, common variant’ hypothesis by demonstrating a
common direction of effect for risk-associated alleles
across populations when power or effect size is limited
[29]. Fourth, they enable the identification of rare or
causal variants by fine-mapping the association signals
that are persistent despite major differences in LD struc-
ture across genetically diverse populations. Along the
Table 1 Landmark and innovative transethnic genetic association analyses*
Trait Gene or locus Platform Comments References
Type 2 diabetes TCF7L2 Haplotype
analysis
Replication of primary signal in WA population and fine-mapping
of second independent signal showing positive selection in WA, EA









Fine-mapping of known LPL gene association in AA with extreme
lipid phenotypes, replication in WA, and showed stronger effect size




APOL1 GWAS Common variants in APOL1 associated with resistance to




SLC2A9 GWAS Replication of a 263 kb association locus (identified in EUR) in an
AA cohort enabled fine-mapping to a 27 kb shared region
[107]
Bilirubin levels UGT1A1 GWAS Replication of previously identified association in this locus in EUR
and ASN cohorts using AFR population; also enabled fine-mapping




GWAS Known risk-associated variants are more common in NA, confer
greater risk and explain the higher observed risk of ALL in Hispanic
children. Illustrates how disease risk analysis can shed light on disease
associations in admixed populations with complex genomic architectures
[109]
T2D HNF1A Exome seq High-throughput sequencing identified rare, novel missense mutation
in a known locus associated with maturity-onset diabetes (MODY3);
association is specific to Latino populations. Recently highlighted in a
review on admixed population analysis
[82,110]
Prostate cancer 15 EUR-specific,
7 multi-ethnic
GWAS Large study encompassing over 40,000 cases and 40,000 controls in
EUR, AFR, JPT, and Latino populations; multi-ethnic analyses help
identify 7 new signals not found in EUR
[111]
BMI BRE, DHX34, other Custom
genotyping
platform
Metabochip analysis across about 30,000 AA individuals confirms 8
EUR BMI loci in AA, identified independent signal in known locus




Multiple Expression array EUR, JPT and CHN populations show large variations in gene expressions
due to differences in allele frequencies of common regulatory eSNPs,




Landmark transethnic FE meta-analysis across nearly 27,000 cases from
5 ethnic minority populations identified 7 novel signals, enabled
fine-mapping of 10 loci, and demonstrated evidence of heterogeneity
compared with EUR studies using MANTRA software
[33]
*GWAS and other forms of genetic association studies have historically and recently provided important insights into disease-related loci. This table highlights a
few notable examples, providing the study phenotypes, key associations (where specific), and details of the study including any unique approach used and the
main findings/advances. Abbreviations: AA, African American; AFR, African; ALL, acute lymphoblastic leukemia; ASN, Asian; BMI, body mass index; CEU, Caucasoid;
CHN, Chinese; EA, East Asian; eSNP, expression single nucleotide polymorphism; EUR, European; FE, fixed effects; GWAS, genome-wide association study; HDLC,
high density lipoprotein cholesterol; JPT, Japanese; LD, linkage disequilibrium; NA, Native American; RE, random effects; T2D, type 2 diabetes; TG, triglycerides; WA,
West African.
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tive trait loci (eQTLs or eSNPs) to identify functionally
or mechanistically important regions (transcription fac-
tor binding sites, microRNA target sites or regulatory
untranslated regions) that affect transcription rate, post-
transcriptional or post-translational regulation or protein
activity. Finally, they illustrate how selective pressure
affects allele frequencies and transmission, when a given
ancestral allele contribute to disease risk. This can be
particularly fruitful when such risk alleles are carried by
individuals from admixed populations.
Replication and prioritization of GWAS candidates
One of the most common motivations for pursuing trans-
ethnic GWASs is to evaluate whether bona fide associationsidentified for a disease or trait in one population also
affect other populations of different genetic ancestries.
In the era of genomic medicine, the identification of
such SNPs that can predict disease risk or therapeutic
response is helpful in evaluating potential clinical or
disease-predictive utility. Moreover, because GWAS
association signals represent only a statistical correlation
between genetic variations and disease or phenotype
status, rather than causation, they are sensitive to
sources of confounding and bias. Concerns about false
positives are further amplified because of the large num-
ber of comparisons, as most standard GWAS plat-
forms capture several hundred thousand to millions
of variants and several tens of millions of variants follow-
ing imputation.
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ies had been to replicate the associations identified in one
population in a second population with a distinct ancestry.
At first these efforts aimed to directly replicate SNP-
specific associations (by direct genotyping only the candi-
date SNP in a second population, rather than performing
an independent GWAS), but it soon became apparent that
achieving direct replication in an independent cohort
posed significant challenges. Some SNPs have been
consistently replicated across multiple ancestral popu-
lations - for example, the primary TCF7L2 variant for
type 2 diabetes (T2D) and the variant in the 9p.21 region
for coronary artery disease. However, such consistent rep-
lications are likely to be the exception rather than the rule,
because many disease or trait-associated SNPs reaching
genome-wide significance do not directly replicate in stud-
ies of populations from a different ancestry. Although the
TCF7L2 and 9p.21 variants have moderate disease odds
ratios (1.25 to 1.3), they have high minor allele frequencies
(MAFs), which significantly aided their detection.
Although some initial putative associations are un-
doubtedly spurious (that is, attributable to population
stratification or genotyping artifacts), the lack of direct
replication could also be attributable to technical and
biological factors, even for a true association [3,30]. For
example, there will be no transethnic replication if there
is significant heterogeneity in the LD structure across
different ethnic populations or if there is significant
heterogeneity in the clinical phenotype or trait. In the
former case, a major biological challenge comes when
allele frequencies differ greatly across populations [31], as
the ancestral allele frequency can also differ, for example,
in HapMap European (CEU) versus African (YRI) popula-
tions. Consequently a given variant may be polymorphic
or monomorphic in the second population, which makes
directional and allele-specific replication challenging. Fur-
thermore, a common variant that is less common or even
rare in a replication population typically indicates that a
greater sample size is needed to achieve comparable statis-
tical power to detect a significant association [32,33].
Nevertheless, many well-established SNPs have been
replicated in transethnic studies. Notable examples in-
clude PTPN22 in RA and inflammatory bowel disease
[34-38], INS in type 1 diabetes [39,40], IL1RL1 in asthma
[41] and TCF7L2 in T2D [33,42]. These results lend
significant confidence and credibility to GWAS, because
the replication of these lead index signals (essentially the
most significantly associated signals, or the fine-mapped
SNP with the strongest P-value in a candidate locus)
in a population with significantly different LD struc-
ture overcomes the concern that a given signal is observed
as a result of population stratification or other confoun-
ders (such as those introduced by environmental or geo-
graphical effects).A recent large-scale review of published transethnic
GWAS results across 28 diseases in European, East Asian
and African ancestries [43] showed that a large proportion
of the associations are caused by common causal variants
that seem to map relatively close to the associated index
genetic markers, indicating that many of the disease risk
variants discovered by GWASs are shared across diverse
populations. Even when power is insufficient to achieve
statistically independent genome-wide significance, recent
large-scale studies using summary-level data have shown
unexpectedly high rates of directional consistency across
transethnic GWAS signals [29].
As power is a function of both the strength of the
association (effect size) and the MAF of the associated
variant, limitations in transethnic replicability of variants
resulting from limited allelic polymorphisms in a replicat-
ing population is a notable challenge. This is particularly
the case in transethnic replication studies that incorporate
resequencing data, which attempt to replicate findings
of rare variants associated with disease. Recently, newer
methods have been proposed for boosting the power of
random effects models to provide multi-variant, gene-
based testing that can be implemented in rare-variant
transethnic association study designs [44].
Finally, despite these successes, new methods that can
assess naturally occurring differences in population allele
frequencies and LD structure are needed because it
remains difficult to know which SNPs are expected
or, conversely, not expected to be ‘replicable’ given inher-
ent genomic architectural differences. Such methods could
help identify a priori a replication population of interest
and also help reduce the frequency of performing ‘replica-
tion’ studies in populations in which the associated variant
is either non-polymorphic or too rare.
Boosting power by large-scale transethnic
meta-analyses
As the cost of genotyping has fallen precipitously since
the first published GWAS (on age-related macular degen-
eration in 2005 [45]), independent efforts led by major
genomics consortia, such as the Continental Origins of
Genetic Epidemiology Network (COGENT), across mul-
tiple continents have since been published or are under-
way, investigating dozens of common heritable traits and
diseases. A clear challenge of using transethnic GWASs
to independently replicate new associations is the limited
sample sizes, particularly if the variant was originally
found in a genetically isolated population. Some studies
have thus focused on finding out whether the directions
of effects across replication cohorts are consistent, ra-
ther than attempting to replicate signals at genome-
wide significance [29,33,46]. Although some consider a
Pnominal <0.05 in a second cohort to be a replication signal,
in most cases, when an independent GWAS has been
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genome-wide significance threshold at P <5 × 10-8 in
European populations [3,30]. These efforts are further
fueled by the challenge that the study power of any single
cohort is limited given the high confidence threshold
required to declare an association as genome-wide signifi-
cance in the context of a large number of comparisons
made in GWASs.
In the past few years, many global genomics consortia
with enormous patient datasets have been used either
in cross-continental mega-analyses directly or, more
frequently, in summary statistic meta-analyses to better
account for the wide ranges of genotyping platforms, gen-
etic ancestry, environmental exposures, and other sources
of sample heterogeneity. Two exemplary consortia that
have published extensively using large transethnic cohorts
include the T2D consortium and the RA consortium
[23,47]. Overall, however, attempts to use transethnic
cohorts for direct replication of GWAS loci have met
with only limited success [31,48,49].
Methodological advances in transethnic
meta-analysis
Although the publication of data from these transethnic
studies is becoming increasingly frequent, these methods
face several challenges, notably the presence of both
genotype and phenotype heterogeneity. For example, not
all SNPs found in one population are polymorphic in an-
other, some disease-associated SNPs have vastly different
MAFs across different populations [50,51], and gene-
environment interactions [52] and differences in study
design or cohort recruitment could add to study hetero-
geneity. The need to appropriately adjust for population
stratification in the presence of heterogeneity opposes
the simultaneous need to optimize study power, a prob-
lem that remains highly challenging in the transethnic
GWAS field.
Existing methods for cross-cohort meta-analysis as-
sume, for the large part, one of two theoretical frame-
works: fixed effects (FE) and random effects (RE) [53-55].
The former assumes that if a true association signal is
identified in one cohort, that association will have a simi-
lar effect size in other cohorts. In contrast, RE models
assume that effect sizes are highly variable, but that they
follow a known (typically the normal) distribution. In the
context of transethnic studies in which heterogeneity is to
be expected, FE methods have limited utility, because of
the typically high variance across studies: transethnic stud-
ies, in comparison with studies in a single ancestry, inevit-
ably show higher inter-cohort heterogeneity.
Although in the presence of heterogeneity the RE model
is more statistically sound, RE methods operate under a
fairly conservative assumption that even null associations
can have greatly varying effect sizes. Consequently, inthese traditional methods, heterogeneity in the effects
observed across populations results either in a down-
estimate of the effect size because some populations do
not show this association (when one obtains a mean esti-
mate of effect), or in an overestimate of the standard
errors that reduces the overall confidence of the asso-
ciation signal identified (by adjusting for heterogeneity).
These are the main reasons that neither of these ap-
proaches are ideal when considering multiple, ethnically
diverse cohorts together in a transethnic GWAS. Their
advantages and limitations have been addressed thor-
oughly elsewhere [56,57].
Two recent approaches, including alternate random
effects (RE-HE) [56] and MANTRA [58], have been pro-
posed to address some of the limitations met by trad-
itional FE or RE models for meta-analysis. Both of these
have been implemented in open-source software and are
publically available. Central to both methods is the goal
of optimizing study power when there is significant
inter-study heterogeneity. Briefly, the approach taken by
Han and Eskin [56] in developing the RE-HE model is
based on the observation that RE methods have less
power than traditional FE models because they assume
an overly conservative model under the null [45]. Thus,
by relaxing this overly conservative assumption, Han
and Eskin demonstrated that the RE-HE model is more
powerful than either traditional RE or FE methods when
there is a true association but significant inter-study
effect heterogeneity [56].
Although the RE-HE method is not specific to trans-
ethnic studies, it is clear that implementing this model
would be particularly helpful. In contrast, Morris [58] in-
troduced MANTRA specifically to address heterogeneity
across studies in transethnic meta-analysis. The primary
advance introduced in MANTRA is taking into account
the expected differences in genetic architecture across
different ethnicities in a transethnic study by using dif-
ferences in the local LD structure across diverse popula-
tions [58]. MANTRA expects populations with similar
genetic ancestries to have more closely matched effect
sizes, while allowing for greater heterogeneity in the effects
observed for more diverse populations. MANTRA has
been shown to have greater power in both detecting shared
associations and fine-mapping causal variants than FE
methods, and where there is correlation between gen-
etic similarity and similarities in effect sizes, MANTRA
performs significantly better than RE.
These methods have been used successfully by a few
transethnic and large-scale meta-analysis efforts, although
their applications have been thus far limited to a few
publications [7,14,33,56,59]. Future work using them
along with functional data from population-specific studies
(such as eQTLs and allele- and tissue-specific transcript
expression) could help further advance these approaches in
Figure 1 Fine-mapping of candidate causal or functional SNPs
by transethnic GWAS. The graph shows the results of association
testing (in the form of the allele frequencies) for a typical locus in three
different populations. In the EUR population, many SNPs in the region
are in close LD, leading to a significant signal for a wide set of SNPs.
However, LD patterns in the ASN population are different, which
enables finer mapping of the causal SNP as being the SNP with the
strongest trait association. However, it is rarely obvious in advance
which additional populations should be studied, as in some populations
(such as AFR in this example) the locus might not be associated
with the trait at all, because of epistatic interactions, phenotype
heterogeneity, or low minor allele frequency/non-polymorphic markers
across the locus. Data shown are based on simulation and do not
reflect the result of any published or unpublished studies. Abbreviations:
ASN, Asian; AFR, African; EUR, European.
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ces. These methods have been compared directly against
other meta-analysis methods in several recent reviews,
including a thorough analysis by Wang et al. [57], who
demonstrated that both RE-HE and MANTRA were
superior to traditional approaches in transethnic meta-
analysis, with RE methods having the poorest power.
Specifically, the power and sensitivity of these methods in
the context of known MAF and population genetic archi-
tectural heterogeneities have been taken into account.
Although MANTRA and RE-HE methods cannot be
truly compared directly because the former uses a Bayesian
framework, at the Bayes’ factor significance threshold rec-
ommended by Morris [58], MANTRA seems to outper-
form RE-HE in nearly all instances except when there is no
heterogeneity in effect sizes across studies [57]. MANTRA
has been used in recent transethnic studies, including a
landmark meta-analysis on T2D by the DIAGRAM con-
sortium with over 76,000 individuals genotyped [33].
However, the use of these new approaches is still lim-
ited, and most recent studies have applied one or a com-
bination of the traditional FE or RE meta-analysis models
[60-63]. We recommend that studies consider implement-
ing, alongside traditional methods, one or more of these
newer, more powerful methods. In addition, it is crucial
that for all such meta-analyses the author should assess
and report a power calculation when discussing the pres-
ence or absence of independent transethnic replication. In
many instances in which traditional methods are used, it
is unclear whether the lack of significance in a replication
cohort is the result of limited power or sample size in the
presence of significant heterogeneity, or truly the absence
of genetic association.
Locus fine-mapping: identifying causal and
functional variants in case-control and quantitative
trait transethnic GWASs
An inherent advantage of transethnic studies is that dem-
onstrating that signals are shared across multiple distant
ancestral populations can help guard against false positives
identified by GWASs due to population-stratification-
related confounding. Although numerous methods have
been identified in attempts to overcome such risks, they
remain a challenge and concern, which is why independ-
ent replication, particularly in a second cohort, is still the
gold standard in the GWAS community. Furthermore,
because association signals in homogeneous populations
are identified across a conserved LD block, it is not clear
which SNP is the most strongly associated with a given
phenotype, and consequently is most likely the functional
or causal variant.
Furthermore, in the past few years, the genomics com-
munity has shifted its focus from locus discovery to identi-
fying casual or functional variants, in response to heavycriticisms of the limited utility of GWAS results and in an
effort to better establish whether there is significant utility
of such genetic information. Although most GWAS
signals are found in non-coding regions of the genome
(either intronic or intergenic regions), it is thought that
some common association signals are proxies that ‘syn-
thetically tag’ the rarer causal or functional mutations in
LD [64]. Based on these principles, deep resequencing
around candidate loci followed by association testing to
identify the most significant disease/trait-associated SNP
within the candidate locus is commonly referred to as
locus fine-mapping. In this approach, the top signal iden-
tified across different populations in a locus where the
signal has been identified in both populations can help
pinpoint the causal or functional variant of interest
(Figure 1). Such methods have been used to successfully
identify biologically plausible candidate gene mutations
[65] and improve the total variance explained by identified
loci by up to 50% [66], as has been shown for LDL.
Although resequencing techniques are becoming
widely available and more economically feasible, geno-
typing is still advantageous in the study of variants with
MAFs greater than 1 to 5%.
This is particularly true with the now widely available,
high-density population-based genome references, such
as the 1000 Genomes project and the ongoing UK-10 K
and Genome Netherlands projects [67,68]. To boost the
power to identify functional or causal variants, several
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sample size and transethnic approaches. This area will
likely benefit from additional development. For example,
one question that remains controversial is whether a
population-specific or mixed-population reference se-
quence panel should be used for genome imputation, to
ascertain untyped markers when attempting to fine-map
admixed populations or populations without a precisely
matching reference panel [69-72].
Towards this goal, transethnic GWAS designs use
naturally occurring differences in the LD patterns sur-
rounding the locus of interest to help identify the
likely causal or functional variants(s). Specifically, it is
expected that the causal or functional variation would
be associated with disease or trait status even in different
populations in which the ancestral or derived haplotype
frequencies differ significantly because of population drift
or under selective pressures. Consequently, this allows the
dissection of the key functional variant from other vari-
ants that are tagging signals on the same haplotype,
because the non-causal tagging signals will be less likely to
be preserved across diverse populations. This is par-
ticularly helpful, for instance, in using populations with
more diverse haplotypes (such as African populations) to
help refine signals from a less diverse group (such as
European). Similarly, local ancestry analysis in admixture
populations such as Mexican or Native American popula-
tions can also be helpful in refining a signal spanning a
large LD block (see below).
Methods such as MANTRA, as discussed above, have
also been effectively implemented in several transethnic
fine-mapping studies - for example, across 14 central
adiposity loci [59] and to discover and fine-map serum
protein loci in European and Japanese cohorts [14].
Extension of MANTRA to additional cohorts and phe-
notypes will probably be fruitful because these newer
algorithms have not yet been widely used to study
transethnic cohorts. This is because most studies so
far still use traditional meta-analysis frameworks to sum-
marize transethnic association findings [41,60,62,63,73].
Several recent studies have shown that transethnic ap-
proaches to fine-mapping can improve the total variance
explained across known association loci [15,74]. A sum-
mary of the methods discussed above and example appli-
cations of these methods in landmark manuscripts are
provided in Table 2.
Using admixture mapping in transethnic study
designs
One of the major observations from transethnic studies
is the limited direct replicability of signals identified in
one population associated with a given phenotype in a
second population of differing ancestry. However, as dem-
onstrated elegantly by Wijmenga and colleagues [75] forfour well-studied GWAS traits, although specific variants
might not be shared between populations, when one also
considers markers in close proximity to the originally
identified markers, the replicability of variants across pop-
ulations is relatively high.
Thus, although genetic studies of a range of phenotypes
across different populations have not yielded associated
loci common to all or even the majority of investigated
ancestry groups, this could be for a variety of reasons
independent of whether this is a truly shared risk- or
phenotype-associated variant: population-specific variants,
differences in allele frequencies, different patterns of LD
across respective populations, and/or low statistical power
from modest sample sizes, as discussed above.
One traditional technique used to identify disease-
association or phenotype-associated regions of the gen-
ome, which was used and advanced before the advent of
high-density genotyping platforms and the GWAS era,
was the use of ancestry-informative markers in admixture
mapping [76,77]. Admixture mapping using populations
that have recently undergone gene flow from two ances-
trally isolated populations, such as African Americans, is a
very powerful method to detect disease variants where
there are substantial allele frequency differences in the
ancestral populations [32,41,57,58]. In broad terms,
the goal of an admixture study 000is to identify the
risk-associated allele (for a given disease) based on the
likelihood of observing an association between a given an-
cestral allele(s) with disease risk [78,79]. Both case-control
and case-only study designs are feasible, with the latter
adding flexibility and reducing the need for a large control
sample size, which can be particularly difficult to ascertain
in admixed populations.
The theoretical framework for admixture-based gen-
etic mapping analysis is complex and beyond the scope
of this review, but it is summarized briefly in Figure 2
(see also several reviews [78-84]). The most commonly
used method is mapping by admixture linkage disequi-
librium (MALD), which uses the fact that the prevalence
of the disease studied is considerably different between
ancestral populations of the admixed cohort [78,79,85].
In contrast to transethnic analyses, in which isolated
populations are investigated, admixture GWASs can help
avoid the bias introduced by confounding in GWASs in
the presence of mild to moderate degrees of population
stratification. Traditional approaches to handling popu-
lation stratification, typically by adjusting for differences
in global ancestry, are challenging and often insufficient in
either ethnically diverse or mixed ancestry populations
(for example, Hispanic or African American cohorts),
given that efforts that focus on simply adjusting for global
ancestry are often insufficient or under-powered [83,86,87].
Methods for local ancestry adjustments have been put
forth as powerful alternatives to controlling for population
Table 2 Methods, tools, literature reviews and resources*
Method or advance Advances and limitations or main findings References
MANTRA transethnic meta-analysis
software
Replication of primary signal in WA population and
fine-mapping of second independent signal showing
positive selection in WA, EA and EUR cohorts. MANTRA
is available as a suite of executables on request from
the author [58]. Major limitation in that it cannot estimate
a joint effect size even for the combined meta-analysis
MANTRA [58]; applications: adiposity
loci [59]; quantification of serum
protein [14]; T2D [33]
RE-HE random-effects method RE and FE models in the context of a meta-analysis with
significant heterogeneity have low power. By relaxing overly
conservative parameters in RE analysis algorithms, RE-HE provides
more power in the presence of inter-study effect heterogeneity.
Metasoft is available as a package [114]; it provides a joint effect
size estimate, but it is the same as the RE estimate
RE-HE algorithm [56]; applications:
endometriosis [115]; bipolar
disorder [18]; multi-tissue eQTLs [116]
Review on replicability of
transethnic association signals
Comprehensive review of literature across 28 diseases in
EA and EUR populations demonstrating high replicability,
sharing of disease alleles and good correlation of effect sizes
[43]
Review on power gains in
meta-analytical approaches
Simulation-based analysis demonstrating that a multi-ethnic
study design provides non-trivial power gains, especially when
AFR populations are used to examine low frequency alleles (MAF <5%)
[117]
Comparative analysis of FE,
RE, RE-HE and MANTRA as a
method for GWAS meta-analysis
Results show that both RE-HE and MANTRA are computationally
efficient and robust methods in accounting for effect size heterogeneity
while providing a boost in power when compared with traditional
meta-analysis methods. Results are provided for both simulations and
application to T2D datasets
[57]
Modified RE-HE for joint analysis
of resequencing data for rare
variant gene-based analysis
Extension of RE-HE to provide a more powerful (than traditional RE)
method to perform rare-variant burden testing in a heterogeneous
resequencing study sample
[44]
*Summary of innovative methods, applications and literature reviews as highlighted in the main text. We summarize the methodological advances, including
those for meta-analysis, any significant or notable limitations, and for reviews. Abbreviations: AFR, African; ALL, acute lymphoblastic leukemia; EA, East Asian; eQTL,
expression quantitative trait locus; EUR, European; FE, fixed effects; GWAS, genome-wide association study; LD, linkage disequilibrium; MAF, minor allele frequency;
RE, random effects; RE-HE, alternate random effects; T2D, type 2 diabetes; WA, West African.
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[81,82], but this has recently been challenged by work from
Shriner et al. [88], who proposed a potentially more power-
ful joint approach to admixture mapping and association
testing that accounts for both global and local ancestry.
Alternatives to adjusting for ancestry differences by
using linear mixed model approaches, which have gained
popularity recently, have only been applied so far to
closely related populations, not to transethnic GWASs.
Consequently, directly merging genotypes from either
ancestrally divergent populations or those that have un-
dergone varying degrees of admixture using traditional
association testing frameworks (such as global ancestry
adjustment using principle component or multi-dimen-
sional scaling) to adjust for population substructure
does not sufficiently control for the risk of confounding
[77,81,89,90]. An inherent advantage of admixture map-
ping is that it bypasses this challenge because its goal is to
firstly assign each allele (risk versus protective) to the
ancestral population, and secondly test if there is a statisti-
cally significant overrepresentation of the allele from one
ancestral lineage across cases versus controls [91].
Admixture mapping approaches, which uses signifi-
cantly fewer tests across the genome, have been success-
fully used to study several traits and phenotypes, including
blood pressure phenotypes in African Americans, forwhich no robust associations had previously been ob-
served using conventional GWAS approaches [92].
Admixture mapping has also been used to identify
loci contributing to various complex traits and diseases,
including body mass index, multiple sclerosis, cholesterol
levels and focal segmental glomerulosclerosis [93-97].
These studies have gained much clinical and epidemio-
logical attention, in part because many of the investigated
phenotypes and diseases occur at unexpected higher rates
in admixed populations, such as Native Americans,
African Americans and Latin Americans [85].
Conclusions and remaining challenges
As the cost of genotyping and high-throughput sequen-
cing technologies continues to drop, consortium-driven
worldwide GWASs of complex diseases and phenotypes
will probably continue to expand to ever larger cohorts,
additional phenotypes and wider ethnic groups. In ad-
dition, coupled with current deep phenotyping and
electronic medical record mining efforts, genomic
medicine is entering an exciting era of phenomics and
phenome-wide association studies (PheWASs), in which
characterization of genetic and environmental effects
across all traits and diseases might be within reach.
Applying the methods discussed here for transethnic
GWASs to PheWASs could be powerful, given the known
Figure 2 Theoretical basis of admixture GWAS study designs. (a) Populations 1 and 2 are two parental populations in which there has been
no gene flow historically. When these populations interbreed the subsequent F1 population includes heterozygotes. Over the course of 5 or 10
generations the chromosome of any given Fn population offspring will include a combination of parental chromosomal ‘bands’. Some loci are
associated with a disease (such as B) and others are not (such as A). (b, c) In a typical GWAS, association testing identifies whether a given allele
(such as T at SNP2) is associated with increased risk for having a disease; this is shown as allele frequencies in the table. (c) If the ancestral
frequency of T at SNP2 is different in two parental populations (1 and 2) and if it is associated with disease, then the population with higher
frequencies of this allele will also have higher risk for disease. One can thus expect to observe higher incidences of disease in individuals carrying
the T allele and also higher incidence of disease in individuals from population 1, in which the T allele is more frequent. This is the premise of
admixture association studies. By ascertaining local ancestry one can determine if an allele that is much more common in one population may
be associated with disease risk. In (b), in a locus with no evidence of association with disease, admixture analysis would find that the minor allele
frequencies (and percentages of individuals of either ancestral populations) do not differ between cases and controls. (d) Graph of the allele
frequencies along the genome. The relative frequency of the allele from population 1 differs between the cases and the controls only at the
locus associated with the disease/phenotype. Thus, in admixed populations, by determining the local ancestry in the cases versus controls, one
can determine if there is an association between an allele associated with ancestry and disease liability.
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ethnic groups.
Without a doubt, new findings from transethnic studies
will enrich our understanding of several issues. First, the
degree to which genetic associations are shared or
population-specific in the presence of either shared or
disparate genetic architecture; second, how architectural
differences in LD patterns might affect the pattern of
genetic association; and third, whether ethnically stratified
disease prevalence is directly attributable to genetic or
gene-environment interactions. New methods, such as
MANTRA and RE-HE, as discussed here, offer more robustand better powered approaches to performing transethnic
meta-analyses.
As the number of GWASs using transethnic and
admixed populations increases, they present new oppor-
tunities for novel study designs using linkage information
at either the variant level or the higher gene or pathway
levels. However, numerous challenges remain for transeth-
nic studies. Specific association markers typically demon-
strate limited replicability in genetically distant cohorts
and it is usually not known a priori which loci should
have a good chance of being shared versus being popula-
tion-specific. Nor is it clear which populations (including
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chance for locus discovery versus fine-mapping.
Wijmenga and colleagues, in their review of existing
literature-reported transethnic GWAS replication rates
across different study populations [75], observed that the
replication rate of loci is high whereas that of individual
SNPs is low. They concluded that many reports of non-
replication in transethnic studies result from studies that
are limited by differences in genetic architecture (some
markers are non-polymorphic or rare in other popula-
tions) but not by the fact that these are not biologically
conserved shared loci. To overcome this challenge, they
advised the use of pathway- and gene-based methods [75].
Although not yet available, recently advanced gene- and
pathway-based methods for GWAS are likely to be easily
applied to transethnic datasets and to require little add-
itional method development [98-100].
Another relevant question that has not been thor-
oughly explored is whether specific populations are more
amenable or useful in a transethnic or admixture analysis;
identifying optimal methods to answer this question in
a locus-specific manner will be difficult. Some methods
have been proposed: constructing marker panels for
admixture studies using an information-theory-based
measure, the expected mutual information score [85];
identifying markers that are most likely to be fine-
mappable by transethnic study designs using LD in-
formation [101]; and identifying populations in which
LD variations are optimal for transethnic [92] or admix-
ture study designs [102]. Finally, Yang and Visscher and
colleagues [103] recently described a linear mixed model
to estimate the genetic variance explained by genome-
wide markers as a method for estimating disease and trait
heritability based on common SNPs. This has been exten-
ded by Coram et al. [20] to consider admixed populations.
The proposed admixture-adjusted measures for trait and
disease heritability will probably have broad applications.
Finally, work has also been done to examine how in-
formation on LD structure differences across ethnically
diverse populations, and variant molecular function, can
be used in a Bayesian framework to improve the power of
association testing [104]. Although much work remains to
be done to maximize the power of such transethnic and
admixture population-based GWAS designs, it is clear
that making use of this information will be important in
both locus discovery and replication in non-European an-
cestral populations and in the identification of functional
or mechanistic variations in the post-GWAS era.Abbreviations
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